Analysis of cell-free DNA (cfDNA) is promising for broad applications in clinical 31 settings, but with significant bias towards late-stage cancers. Although recent studies have 32 discussed the diverse and degraded nature of cfDNA molecules, little is known about its 33 impact on the practice of cfDNA analysis. Here we reported a new targeted sequencing by 34 combining single-strand library preparation and target capture (SLHC-seq). By applying 35 the new technology in plasma cfDNA from pancreatic cancer patients, we achieved higher 36 efficiency in analysis of mutations than previously reported using other detection assays. 37 SLHC-seq rescued short or damaged cfDNA fragments along to increase the sensitivity 38 and accuracy of circulating-tumor DNA detection. Most importantly, we found that the 39 small mutant fragments are prevalent in early-stage patients, which provides strong 40 evidence for fragment size-based early detection of pancreatic cancer. Collectively, the 41 new pipeline enhanced our understanding of cfDNA biology and provide new insights for 42 liquid biopsy. 43 44 MAIN TEXT 45 65 sequencing.(Aravanis et al, 2017; Zill et al, 2015) Moreover, the noninvasive nature of cfDNA 66 analysis enables doctors to monitor disease progression.(Couraud et al, 2014; Murtaza et al, 2013; 67 Zill et al, 2015) However, cfDNA analysis using large-scale next-generation sequencing (NGS) 68 has been largely confined to advanced or metastatic cancers, in which the ctDNA ( circulating-69 tumor DNA ) fraction is higher and is more readily detectable.(Gorgannezhad et al, 2018; Haber 70 & Velculescu, 2014) Detection of ctDNA in early-stage cancers is still filled with cautionary tales 71 that highlight the technical challenges in this field. Recently, Velculescu et al reported improved 72 targeted error correction sequencing ( TEC-Seq ) as an efficient approach for the detection of 73 ctDNA in early-stage colorectal, ovarian, breast, and lung cancers, with a detection rate ranging 74 from 59% to 71%.(Phallen et al, 2017) The massive parallel sequencing approach provides an 75 applicable paradigm guiding cfDNA analysis in early-stage cancers. 76 However, the performance of existing approaches is limited in cfDNA analysis in early-77 stage pancreatic cancers. This limitation may be partially because of a lower ctDNA content in 78 the circulation of pancreatic cancers.(Aravanis et al, 2017) Moreover, the biological features of 79
Introduction
Pancreatic cancer is among the most lethal malignancies, with a 5-year survival rate of 47 approximately 8%, (Siegel et al, 2017) and is predicted to be the second leading cause of cancer-48 related death by the year 2030. (Rahib et al, 2014) Early diagnosis and personalized treatment can 49 greatly benefit patients with this disease. (Kamisawa et al, 2016; Lennon et al, 2014) Because 50 targeted therapies have been reported to be highly effective for a subset of cancer patients with 51 actionable mutations, characterizing pancreatic cancer at the genetic level holds great promise for 52 precision medicine in the near future. (Garrido-Laguna & Hidalgo, 2015; Mardis, 2012; 53 Witkiewicz et al, 2015) 54 However, genomic profiling of pancreatic cancer is challenging due to several limitations. 55 First, pancreatic lesions often have a high stromal cell content, which may complicate the analysis 56 of tissue sequencing. (Moffitt et al, 2015; Neesse et al, 2015; Waddell et al, 2015) diversity of these molecules, particularly degraded fragments with nicks in either strand. In 2012, 84 Meyer et al introduced single-stranded library preparation for sequencing highly degraded DNA 85 samples from an extinct archaic human. (Meyer et al, 2012) The single-strand approach has shown 86 higher efficiency in the recovery of degraded and shorter DNA fragments. (Gansauge et al, 2017; 87 Glocke & Meyer, 2017) Several recent studies have also shown that single-strand library 88 preparation improved the recovery of cfDNA from cancer patients, (Snyder et al, 2016) 89 transplantation recipients (Burnham et al, 2016) and maternal plasma. (Vong et al, 2017) It is of 90 great significance to determine whether single-strand library preparation could indeed improve 91 the performance of cfDNA analysis in clinical practice, especially in early-stage cancers. 92 Thus, we developed a single-strand library preparation and hybrid-capture-based cfDNA 93 sequencing (SLHC-seq ) approach and applied it to perform cfDNA profiling in a clinical cohort 94 of 112 patients with pancreatic cancers and 28 healthy volunteers. SLHC-seq showed high 95 sensitivity and specificity for detecting ctDNA in patients with pancreatic cancer across all stages. 96 Using this new approach, the genomic landscape cfDNA was highly comparable to the results 97 from direct tumor tissue sequencing. More importantly, single-strand library preparation 98 efficiently enriched short cfDNA fragments (< 100 bp), which may prominently originate from 99 degraded ctDNA fragments with nicks in either strand. We demonstrated that the ability to 100 recovery these degraded fragments directly improved the sensitivity and accuracy of the detection 101 of KRAS mutations in early-stage pancreatic cancer. Our observations highlight that the biologic 102 features of ctDNA may ultimately determine the ability to detect precancerous or very small 103 cancer lesions. The single-strand approach could be a powerful tool for large-scale mutation 104 measurements of cfDNA and has the potential to be generalized to cfDNA analysis for other 105 common cancers.
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Results
108
Single-strand library preparation and hybrid-capture-based cfDNA sequencing 109 Based on the hypothesis that single-strand DNA library preparation is, in principle, more sensitive 110 to recover the full spectrum of cfDNA fragments from plasma, we developed a single-strand 111 library preparation and hybrid-capture-based cfDNA sequencing methodology (SLHC-seq, Fig.   112 1A,B). First, we selected the 62 most recurrently mutated genes in common cancer types covering all exons of these 62 genes, which encompassed an approximately 211-kb region (Table   117   S1 ). Theoretically, the single-strand library preparation should improve the conversion efficiency 118 of degraded DNA fragments (especially fragments with nicks in either strand) compared with that 119 of conventional methods. The following steps were similar to those in the targeted sequencing of 120 cancer tissue. Bioinformatics analyses were performed to identify tumor-specific mutations and 121 eliminate potential artifacts ( Fig. S1) . These analyses mainly included the following: (i) using . S1 ). 128 We next compared the performance of SLHC-seq with that of conventional NGS methods 129 for detecting known cancer-specific mutations, including single nucleotide variants and small 130 insertions and deletions, in reference genomic DNA. Generally, SLHC-seq and conventional 131 approaches both showed high sensitivity and specificity in the analysis of mutations with higher 132 fractions. Initially, with 1 ng of DNA input, SLHC-seq, compared with the conventional 133 approach, showed a significantly higher efficiency for the detection of mutations in the reference 134 genome ( detection rate: 75% vs. 45%, respectively, p<0.01, Fig. S2 ). Then, we evaluated the 135 performance of SLHC-seq using a mixture of references at different dilutions. Initially, with 5 ng 136 of DNA input, SLHC-seq identified over 50%, 70%, 92% and 92% mutations in 10, 5, 3,2-fold 137 dilutions, respectively. Further analysis of the variant alleles achieved high concordance to the 138 expected fraction of mutations (adjusted R 2 =0.94; p<0.0001, Fig. S2 , Table S2 ), as well as high 139 sensitivity and specificity. Overall, the analytical sensitivity was 92%, 88% and 83% for detecting 140 mutations using a threshold allele fraction of 0.5%, 0.2% and 0.1%, respectively. No false-141 positive mutations of the identified alleles were detected in the blank control using the SLHC-seq 142 approach. According to the results, an allele fraction of 0.5% was determined as the threshold for 143 identifying cancer-specific mutations in plasma cfDNA.
145
Detection of KRAS mutations using SLHC-seq in the circulation of pancreatic cancers 146 Of the 112 included patients, 70 were histologically diagnosed as having pancreatic ductal 147 adenocarcinoma (PDAC), 16 were intra-ductal papillary mucinous neoplasm (IPMN), and 16 148 were clinically diagnosed pancreatic cancer (CPC) (Fig. S3 , Table S3 ). The median cfDNA 149 concentration across the pancreatic patient group was 16.2 ng/ml (IQR: 9.3-25.9 ng/ml), which 150 was significantly higher than that in the healthy individual group (median 3.2, p<0.0001, 151 Wilcoxon-Mann-Whitney test ). The total cfDNA concentration of the patients was independent 152 of tumor stage and CA19-9 value, while it increased with radiological tumor sizes in patients with 153 localized PDAC (spearman rho=0.4021, p=0.0042, Fig. S3 ). 154 Detection of KRAS hotspot mutations in the circulation was often used for diagnosis of 155 pancreatic cancer. We compared the performance of our approach in measuring KRAS mutations 156 with that in previous reports using PCR-or NGS-based methods ( Table S4 ). (Allenson et al, 157 2017; Berger et al, 2016; Brychta et al, 2016; Cheng et al, 2017; Cohen et al, 2017; Hadano et al, 158 2016; Kim et al, 2018; Kinugasa et al, 2015; Le Calvez-Kelm et al, 2016; Pietrasz et al, 2017; 159 Sausen et al, 2015; Sefrioui et al, 2017; Takai et al, 2015) Across 13 high-quality studies, the 160 detection rate of the KRAS mutations in plasma ranged from to 21% to 76% ( Fig. 2A ). In our 161 cohort, which included a substantial proportion of early-stage disease patients, tumor-specific 162 mutations were detected in 88% (99/112) of patients, with KRAS hotspot mutations detected in 163 70% [ 95% confidence interval (CI): 62-79% ] of patients ( Fig. 2B ). Of note, SLHC-seq largely 164 outperformed most reports using the ddPCR method in the detection of KRAS mutations in early-165 stage diseases. Using the SLHC-seq approach, the detection of KRAS mutations served as an 166 efficient marker to distinguish PDAC from healthy individuals in our cohort [AUC (area under 167 curve): 0.863, 95% CI: 0.830-0.898, Fig. 2C ]. By utilizing a combination of the KRAS, TP53, 168 CDKN2A and SMAD4 genes, we achieved a higher performance in the diagnosis of PDAC 169 (AUC: 0.921, 95% CI: 0.890-0.956, sensitivity: 80%, specificity: 100%, Fig. 2D ). Diagnostic 170 accuracy was highest when using the full targeted panel, with an AUC of 0.951 (95% CI: 0.932-171 0.983) with an optimum specificity of 100% and sensitivity of 89%. Additionally, the detection of 172 mutations using the full targeted panel also had the ability to distinguish IPMN from PDAC 173 patients (AUC: 0.837, 95% CI: 0.821-0.979, specificity: 87.5%, sensitivity: 66.2% ).
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Of note, multiple KRAS hotspot mutations, including G12D (n= 67 ), G12C ( n=30 ), 175 were detected as well as other hotspot mutations at a lower prevalence ( Fig. 2E ). We identified 176 22 samples with a dominant KRAS clone concurrent with sub-clonal KRAS mutations with lower 177 allele fraction, suggesting that these patients may harbor multiple KRAS mutations in tumor cfDNA between the two groups was similar (median: 161 vs. 162 bp ). Utilizing single-strand 184 library preparation, we explored the fragment length of cfDNA with a focus on the KRAS gene, 185 given the extremely high prevalence of KRAS mutations in pancreatic cancers. Interestingly, a 186 large fraction of patients with pancreatic tumors have mutated KRAS fragments below 100 bp, 187 while the fragments containing wild-type KRAS alleles of these patients are homogenously 188 approximately 160 bp in length ( Fig. 3A ) . A pooled analysis of 78 patients showed that the 189 ctDNA fragments bearing the KRAS mutant alleles, which originated from the pancreatic cancer, 190 were significantly shorter than their wild-type counterparts (median: 135 vs. 164 bp, p<0.0001, 191 Fig. 3B ). 192 Strikingly, the shortened fragment length was more pronounced in pre-cancerous IPMN 193 and early-stage PDAC (stage I/II ) patients. For example, in one case with IPMN ( PC092 ), the 194 fragments bearing the KRAS G12D and KRAS G12C allele were enriched in the region with a shorter 195 length, and a dominant peak 75 bp in size ( Fig. 3C ). In another patient with stage II resectable 196 PDAC (PC076 ), the distribution of fragments bearing the KRAS G12D allele also showed 197 significant deviation from the wild-type fragments with a dominant peak 85 bp in length ( Fig. 3D   198 ). In contrast, in an advanced-stage patient (PC216 ) with a high mutated KRAS fraction ( ~25% 199 ), we observed a broad distribution of mutated fragments including a major proportion of 200 fragments that overlapped with the wild-type fragments at a peak approximately 135-180 bp in 201 length ( Fig. 3E ). The median length of the mutated fragment in IPMN ( n=10 ), early-stage ( 202 n=58 ), and advanced-stage ( n=10 ) PDAC was approximately 80, 140, 160 bp, respectively ( 203 p<0.0001, Fig. 3F-G ) , while the wild-type counterparts had a length of ~160 bp across the 204 subgroups ( Fig. 3F ). Of note, the relative wide distribution of wild-type fragments also included 205 a small proportion of overlapping short fragments with the KRAS mutants, possibly as a result of 206 the heterozygous features of KRAS mutations. 207 Subsequently, the length of fragments was binned into subgroups (60=0-60 bp, 70=71-70 208 bp, etc. ), and the mutated-to-wild-type fragment ratio was calculated for each interval. The 209 proportion of the fragments bearing KRAS mutations reached the maximum in the interval of 60-210 100 bp and sharply declined thereafter. The proportion of the KRAS mutated fractions declined to 211 less than 5% for regions of 150-200 bp in length. Importantly, we found that the ability of library 212 preparation methods to enrich these shorter mutated fragments had a significant impact on the 213 performance of detecting KRAS mutations in plasma. The detection rate of KRAS mutations 214 significantly decreased when setting the threshold at 100 bp or 160 bp (100 bp: 0.70 vs. 0.51, 215 respectively, p<0.05; 160 bp: 0.70 vs. 0.42, respectively, p<0.05, Fig. 3H ). The ability to recover 216 ultra-short fragments also affected the quantification of KRAS mutations in the plasma of patients 217 with pancreatic cancer (Fig. 3I ).
219
Genomic landscape of cell-free DNA in patients with pancreatic cancer 220 We next explored the genomic landscape of cfDNA in pancreatic cancer using SLHC-seq. 221 Generally, we identified 791 somatic mutations in the plasma of 88% (99/112 ) patients ( 222 approximately 4000-fold coverage, Fig. S4 ). In contrast, 8 mutations were detected in the plasma 223 of the healthy controls (n=28 ) without any known . oncogenic or truncating alleles. The average 224 burden of cancer-related mutations was significantly higher in the plasma of patients with 225 detectable ctDNA than that in healthy individuals ( 8.0 vs. 0.29 per individual, p<0.01).Mutations 226 in the TP53, KRAS, CDKN2A and SMAD4 genes were detected in 86%, 79%, 70%, and 58% of 227 plasma cfDNA samples, respectively. In addition to these driver genes, we also observed a high 228 prevalence of mutated genes in the chromatin-remodeling pathway (KDM6A, AIRD1A, and 229 PBRM1 ) and axon guidance ( ROBO1, BOBO2 ) ( Fig. 4 A-B ). KRAS mutations (KRASG 12D 230 and KRAS G12V ) were the most recurrent mutations in the cohort, and we also observed R175H 231 and R273H mutations of TP53, both frequently present across cancers. In addition, we observed Comparison of cfDNA profiling and tissue-based sequencing of pancreatic cancers 243 We next compared the cfDNA profiling results in our cohort and tissue-based sequencing data 244 from 4 publicly available cohorts comprising 922 pancreatic cancer patients. For consistency, the 245 top 15 mutated genes with prevalence over 5% in cfDNA were included in the final analysis. 246 Generally, the cfDNA profiling in patients with detectable ctDNA was largely consistent with the 247 results of the tissue-based sequencing database. The prevalence of KRAS, TP53, CDKN2A and 248 SMAD4 mutations was highly correlated in plasma cfDNA and tissue-based cohorts (Fig. 5A ). 249 The mutational prevalence of the most commonly mutated genes in cfDNA was significantly 250 associated with the mutational prevalence in tumor tissues (adjusted R 2 =0.456, p=0.0057, Fig. S5 
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). However, there was a significant discrepancy in the prevalence of KDM6A (67% vs. 13%, 252 p<0.001 ) and STK11 ( 56% vs. 6%, p<0.001 ) between ctDNA profiling and tissue-based 253 sequencing ( Figure 5A,B ). The prevalence of ROBO1 mutations was also not uniform across 254 the tissue-based sequencing dataset. After the removal of KDM6A, STK11 and ROBO1, we 255 observed a stronger correlation of the genomic landscape of cfDNA and tumor tissue profiling 256 (adjusted R 2 =0.8723, p=5.47e-06, Fig. 5C ). The amino acid changes of KRAS predicted by 257 cfDNA profiling were highly consistent with tissue-based sequencing (cBioPortal, Fig. 5D ). 258 Additionally, we assessed the concordance of mutations in cfDNA and DNA from paired 259 tumor tissues ( n=17, Fig. S5 ). Tumor cellularity ranged approximately from 1% to 15% in the 260 biopsy tissue. The concordance of KRAS, TP53, and CDKN2A alternations between tissue DNA 261 and cfDNA was 75.3%, 58.8%, and 41.2%, respectively ( Fig. 5E, Table S2 ). SMAD4 mutations 262 were sporadically detected in 3 plasma samples and 2 tissue samples. 263 264 ctDNA level and disease burden 265 In our study set, 74 patients were followed-up for a median time of approximately 2 years. The 266 median overall survival of the patients was 15.9 months. Higher levels of CA19-9, CA125, CEA 267 and total cfDNA concentration strongly correlated with poorer overall survival (Table S5) . 268 Allele fraction of the mutations was previously reported as an indicator of plasma ctDNA 269 burden. However, the concentration of total cfDNA is not specific to the specific cancer and is 270 associated with conditions such as cancer-related inflammation. Thus, we estimated both the 271 relative and absolute levels of KRAS mutations using the fraction of mutant-to-wild-type 272 fragments and mutated ctDNA copies per ml in blood (Fig. 6A ). The copies of KRAS mutated 273 fragments (copies/ml ) was associated with the mutant allele fraction and was also affected by 274 total cfDNA quantity ( R 2 =0.4456, p<0.0001, Fig. 6B ). A higher KRAS mutant fraction was 275 associated with a poor prognosis (HR=2.1, 95% CI: 0.9-4.8, p=0.077, Fig. 6C ) but the difference 276 did not reach significance. In contrast, the absolute quantification of KRAS mutations ( copies/ml 277 ) directly marked patients with a worse prognosis to a good prognosis ( HR=4.3, 95% CI: 2.1-9.1, 278 p<0.001, Fig. 6D ). After adjusting for AJCC stage, the absolute quantification of KRAS 279 mutations still directly marked patients with a worse prognosis (HR=2.9, 95% CI: 1.4-6.3, 280 p=0.007, Fig. 6E-F ). In the multivariable analysis, the copy number was a significant marker of 281 OS independent of AJCC Stage, CA19-9, CA125 and CEA level (HR: 3.3, 95% CI: 1.1-10.6; 282 p=0.037, cox proportional hazards model, Table S6 ). Together, our results suggest that accurate 283 quantification of KRAS mutations in plasma may provide a useful marker for prognostic 284 prediction in patients with pancreatic cancer across all stages. tumor-derived mutations that may evolve during early tumorigenesis, tumor progression, and drug 319 resistance. 320 Next, we tried to analyze the fragmentation pattern of cfDNA molecules to find out why 321 SLHC-seq may improve the detection of tumor-derived signals. In previous reports, the periodical 322 shortening pattern of ctDNA fragments has been well described in xenograft animal models or in Compared with their experimental pipelines, the advantages of the single-strand library 327 preparation were to recover the full spectrum of cfDNA fragments. First, the different shortening 328 pattern of cfDNA and ctDNA in our results was consistent with these previous reports. Then, as 329 the emergence of KRAS hotspot mutations has been globally recognized as the initialization of 330 pancreatic neoplasia, analyzing fragments bearing KRAS oncogenic mutations provides an ideal 331 model for further exploring the biological features of ctDNA during early tumorigenesis. Here, 332 we identified a substantial subset of KRAS mutated fragments with a length less than 100 bp, and 333 this phenomenon was more pronounced in early-stage disease. Strikingly, almost all fragments 334 bearing KRAS mutations were enriched at the region of less than 100 bp in length in quite a large 335 portion of patients. The enrichment of ultra-short fragments ( <100 bp ) in ctDNA has hardly been 336 reported before. Based on previous reports, we thought these observations could be more Profiling somatic alternations has become routine for cancer patients, but the non-invasive nature 400 of cfDNA analysis makes it promising for broad application in terms of clinical use. We 401 introduced a unique application of single-strand library preparation to recover degraded or short 402 cfDNA fragments in conception. Here we refined the genomic landscape of cell-free DNA in 403 patients with pancreatic cancer, and found strong evidence that fragmentation pattern of ctDNA 404 may profoundly affect the detection of precancerous or very small cancer lesions. We further 405 demonstrated the clinical significance of this approach that high efficient cfDNA analysis could 406 be an alternative to tissue-based sequencing and efficient biomarkers for pancreatic cancer in Single-strand library preparation, targeted sequencing and bioinformatics analysis 430 The full details of the DNA extraction, library preparation, NGS and bioinformatics metrics are 431 presented as below. Generally, cfDNA was first denatured into single-strand fragments after end 432 repair. Then, these fragments were processed for library construction and hybrid-capture of 433 targeted regions covering all exons of these 62 genes, which encompassed approximately a 221-434 kb region (Table S1 ). We achieved approximately 4,000-fold coverage of sequencing. FreeBayes genes. Briefly, HE, HBA and HBB blocking reagents were added to the 1000 ng pooled pre-475 libraries and completely dried using a heated spin vacuum. The mixture was reconstituted in 7.5 476 μl of VHB1 hybridization buffer plus 3 µl of VHE1 hybridization enhancer. The mixture was next 477 denatured at 95°C for 10 minutes and immediately transferred to a hybridization oven preheated 478 to 47°C. The capture probes were added, and the mixture was quickly mixed and transferred to a 479 thermocycler for hybridization incubation following the manufacturer's protocol. After 480 hybridization, target DNA libraries captured by the biotinylated probes were pulled down using 481 M270 Dynabead streptavidin beads (Thermo Fisher Scientific, Cat# 65306). Briefly, 30 μl of 482 M270 beads were washed twice with 1× Binding Wash Buffer, and the supernatant was removed. 483 Pre-library pools were added and mixed thoroughly with the beads by repeated pipetting, and the 484 mixture was incubated on a rotator at 47°C for 45 minutes. After incubation for the probes to bind 485 to the beads, 100 μl of 1× Transfer Buffer pre-warmed to 47°C was added to the mixture, and the 486 whole content was transferred to a magnetic stand. The supernatant was quickly removed and 487 discarded as soon as it turned clear, and the beads were washed twice using 1× Stringent Wash Table S5 . Univariate and multivariable survival analysis of the patient cohort. 547 *NOTE: Table S4 -S5 were listed at the end of the manuscript. Table S1-S3 were not uploaded because of the large 548 size. We are pleased to provide the tables or raw data when necessary. first denatured into single-strand DNA (ssDNA) fragments. Then, the ssDNA fragments were ligated with a unique 815 molecular identifier. The pre-library was enriched using hybridization and magnetic-beads capture and then subjected 816 to high-throughput sequencing. 817 shorter fragments has a great impact on the detection of KRAS hotspot mutations in plasma (blue line), and the 835 mutated-to-wild-type fraction of fragments bearing KRAS alleles reached the highest in the interval of 60-100 bp and 836 declined sharply thereafter (red line). Ii) Ultra-short fragments (<100 bp) accounted for a quite high proportion of 837 total KRAS mutated fragments in a substantial group of patients with pancreatic cancer. 
